Characteristics of people living with HIV in British Columbia from 2005 to 2016 included in the study and in each analysis*
| Characteristic | No. (%) of participants† n = 3301 | Time Dx-Tx | Time Tx-Vx | ||||
|---|---|---|---|---|---|---|---|
| No. (%) of participants pre-STOP† n = 1601 | No. (%) of participants post-STOP† n = 1700 | p value | No. (%) of participants pre-STOP† n = 998 | No. (%) of participants post-STOP† n = 1981 | p value | ||
| Age, yr‡ | 0.0005 | < 0.0001 | |||||
| < 30 | 719 (21.8) | 320 (20.0) | 399 (23.5) | 126 (12.6) | 421 (21.3) | ||
| 30–39 | 977 (29.6) | 488 (30.5) | 489 (28.8) | 302 (30.3) | 575 (29) | ||
| 40–49 | 929 (28.1) | 493 (30.8) | 436 (25.6) | 323 (32.4) | 560 (28.3) | ||
| ≥ 50 | 676 (20.5) | 300 (18.7) | 376 (22.1) | 247 (24.7) | 425 (21.5) | ||
| Gender | 0.0187 | 0.5013 | |||||
| Women | 582 (17.6) | 308 (19.2) | 274 (16.1) | 175 (17.5) | 328 (16.6) | ||
| Men | 2719 (82.4) | 1293 (80.8) | 1426 (83.9) | 823 (82.5) | 1653 (83.4) | ||
| Ethnicity | 0.0626 | 0.0662 | |||||
| White | 1831 (55.5) | 893 (55.8) | 938 (55.2) | 581 (58.2) | 1074 (54.2) | ||
| Non-white | 921 (27.9) | 422 (26.4) | 499 (29.4) | 251 (25.2) | 574 (29.0) | ||
| Unknown | 549 (16.6) | 286 (17.9) | 263 (15.5) | 166 (16.6) | 333 (16.8) | ||
| Health authority‡ | 0.0138 | 0.6474 | |||||
| Fraser | 787 (23.8) | 348 (21.7) | 439 (25.8) | 240 (24.0) | 496 (25.0) | ||
| Interior | 215 (6.5) | 104 (6.5) | 111 (6.5) | 59 (5.9) | 121 (6.1) | ||
| Northern | 190 (5.8) | 99 (6.2) | 91 (5.4) | 50 (5.0) | 100 (5.0) | ||
| Vancouver Coastal | 1690 (51.2) | 824 (51.5) | 866 (50.9) | 536 (53.7) | 1038 (52.4) | ||
| Vancouver Island | 366 (11.1) | 192 (12.0) | 174 (10.2) | 109 (10.9) | 207 (10.4) | ||
| Unknown | 53 (1.6) | 34 (2.1) | 19 (1.1) | < 5 | 19 (1.0) | ||
| CD4 count, cells/μL‡ | < 0.0001 | < 0.0001 | |||||
| ≥ 350 | 1259 (38.1) | 427 (27) | 832 (49) | 192 (19.2) | 1022 (51.6) | ||
| 200–349 | 530 (16.1) | 225 (14) | 305 (18) | 336 (33.7) | 463 (23.4) | ||
| < 200 | 724 (21.9) | 340 (21) | 384 (23) | 461 (46.2) | 482 (24.3) | ||
| Not measured | 788 (23.9) | 609 (38) | 179 (11) | 9 (0.9) | 14 (0.7) | ||
| HIV acquisition risk group | < 0.0001 | < 0.0001 | |||||
| gbMSM | 1359 (41.2) | 562 (35) | 797 (47) | 357 (35.8) | 913 (46.1) | ||
| PWID | 733 (22.2) | 474 (30) | 259 (15) | 276 (27.7) | 351 (17.7) | ||
| Heterosexual or other | 834 (25.3) | 382 (24) | 452 (27) | 259 (26.0) | 488 (24.6) | ||
| Unknown | 375 (11.4) | 183 (11) | 192 (11) | 106 (10.6) | 229 (11.6) | ||
| Suppressed eventually | 0.0329 | NA§ | |||||
| No | 322 (9.8) | 138 (8.6) | 184 (10.8) | NA§ | NA§ | ||
| Yes | 2979 (90.3) | 1463 (91.4) | 1516 (89.2) | NA§ | NA§ | ||
| First-line ART class¶ | NA¶ | < 0.0001 | |||||
| INSTI | NA¶ | NA¶ | NA¶ | 5 (0.5) | 365 (18.4) | ||
| NNRTI | NA¶ | NA¶ | NA¶ | 405 (40.6) | 675 (34.1) | ||
| PI | NA¶ | NA¶ | NA¶ | 584 (58.5) | 852 (43.0) | ||
| INSTI + PI, INSTI + NNRTI, or INSTI + PI + NNRTI | NA¶ | NA¶ | NA¶ | < 5 | 82 (4.1) | ||
| Other | NA¶ | NA¶ | NA¶ | 0 (0) | 7 (0.4) | ||
| Viral load, log10 copies/mL, median (Q1, Q3)¶ | NA¶ | NA¶ | NA¶ | NA¶ | 4.92 (4.40, 5.00) | 4.78 (4.24, 5.00) | < 0.0001 |
Note: ART = antiretroviral treatment; gbMSM = gay, bisexual and other men who have sex with men; INSTI = integrase strand-transfer inhibitor; NA = not applicable; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PWID = people with history of injection drug use; Q1 = 25th percentile; Q3 = 75th percentile; STOP = Seek and Treat for Optimal Prevention of HIV/AIDS initiative; time Dx-Tx = time from HIV diagnosis to ART initiation; time Tx-Vx = time from ART initiation to viral suppression.
↵* For time Dx-Tx analysis, CD4 count was the only selected confounder; for time Tx-Vx analysis, selected confounders included health authority, CD4 count, HIV acquisition risk group and ART type.
↵† Unless indicated otherwise.
↵‡ Variables were measured at the time of HIV diagnosis (for overall and time Dx-Tx analysis) or at ART initiation (for time Tx-Vx analysis).
↵§ All participants in time Tx-Vx analysis were virologically suppressed.
↵¶ Variables were measured only at the time of ART initiation.